TY - JOUR
T1 - Sepsis-induced immunosuppression
T2 - From cellular dysfunctions to immunotherapy
AU - Hotchkiss, Richard S.
AU - Monneret, Guillaume
AU - Payen, Didier
N1 - Funding Information:
The authors would like to thank P. Swanson (Professor of Pathology, University of Washington School of Medicine in Seattle, Washington, USA) for providing the immunohistochemical images of patient spleens used in figure 2.R.S.H. is supported by US National Institutes of Health grants GM44118 and GM55194. G.M. is supported by funding from the Hospices Civils de Lyon.
PY - 2013/12
Y1 - 2013/12
N2 - Sepsis-which is a severe life-threatening infection with organ dysfunction-initiates a complex interplay of host pro-inflammatory and anti-inflammatory processes. Sepsis can be considered a race to the death between the pathogens and the host immune system, and it is the proper balance between the often competing pro-and anti-inflammatory pathways that determines the fate of the individual. Although the field of sepsis research has witnessed the failure of many highly touted clinical trials, a better understanding of the pathophysiological basis of the disorder and the mechanisms responsible for the associated pro-and anti-inflammatory responses provides a novel approach for treating this highly lethal condition. Biomarker-guided immunotherapy that is administered to patients at the proper immune phase of sepsis is potentially a major advance in the treatment of sepsis and in the field of infectious disease.
AB - Sepsis-which is a severe life-threatening infection with organ dysfunction-initiates a complex interplay of host pro-inflammatory and anti-inflammatory processes. Sepsis can be considered a race to the death between the pathogens and the host immune system, and it is the proper balance between the often competing pro-and anti-inflammatory pathways that determines the fate of the individual. Although the field of sepsis research has witnessed the failure of many highly touted clinical trials, a better understanding of the pathophysiological basis of the disorder and the mechanisms responsible for the associated pro-and anti-inflammatory responses provides a novel approach for treating this highly lethal condition. Biomarker-guided immunotherapy that is administered to patients at the proper immune phase of sepsis is potentially a major advance in the treatment of sepsis and in the field of infectious disease.
UR - http://www.scopus.com/inward/record.url?scp=84888325490&partnerID=8YFLogxK
U2 - 10.1038/nri3552
DO - 10.1038/nri3552
M3 - Review article
C2 - 24232462
AN - SCOPUS:84888325490
SN - 1474-1733
VL - 13
SP - 862
EP - 874
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 12
ER -